相似文献
1
CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.
Drug Metab Dispos. 2012 Jan;40(1):18-24. doi: 10.1124/dmd.111.041400. Epub 2011 Sep 27.
2
Metabolomic screening and identification of the bioactivation pathways of ritonavir.
Chem Res Toxicol. 2011 Dec 19;24(12):2109-14. doi: 10.1021/tx2004147. Epub 2011 Nov 17.
3
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
J Med Econ. 2012;15(4):796-806. doi: 10.3111/13696998.2012.691927. Epub 2012 Jun 7.
4
Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
Phytother Res. 2012 Oct;26(10):1490-5. doi: 10.1002/ptr.4593. Epub 2012 Feb 4.
5
Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Antiviral Res. 2003 Aug;59(3):173-80. doi: 10.1016/s0166-3542(03)00107-4.
6
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40. doi: 10.1097/00126334-200408150-00006.
7
Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.
HIV Med. 2008 May;9(5):270-6. doi: 10.1111/j.1468-1293.2008.00558.x. Epub 2008 Mar 10.
8
Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26.
9
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
Pharmacotherapy. 2023 Jul;43(7):638-649. doi: 10.1002/phar.2703. Epub 2022 Jun 8.
10
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS. 2005 Apr 29;19(7):685-94. doi: 10.1097/01.aids.0000166091.39317.99.
引用本文的文献
1
Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir/Ritonavir in HIV/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease-Drug-Drug Interaction (DDDI).
Clin Pharmacokinet. 2025 May 5. doi: 10.1007/s40262-025-01493-5.
2
Expression of Enzyme in Human Liver Tissue of HIV and HCV Patients.
Medicina (Kaunas). 2023 Jun 27;59(7):1207. doi: 10.3390/medicina59071207.
3
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28.
4
Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system.
Microb Pathog. 2022 Jul;168:105608. doi: 10.1016/j.micpath.2022.105608. Epub 2022 May 30.
5
Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Mol Divers. 2022 Oct;26(5):2613-2629. doi: 10.1007/s11030-021-10358-5. Epub 2022 Jan 9.
6
Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIV-related antivirals.
Int J Mass Spectrom. 2020 Sep;455:116370. doi: 10.1016/j.ijms.2020.116370. Epub 2020 Jun 15.
7
Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?
Biochimie. 2020 Dec;179:266-274. doi: 10.1016/j.biochi.2020.08.018. Epub 2020 Sep 3.
8
Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798. doi: 10.1161/CIRCEP.120.008798. Epub 2020 Jul 9.
9
Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain.
Transpl Infect Dis. 2020 Oct;22(5):e13372. doi: 10.1111/tid.13372. Epub 2020 Jul 1.
10
CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor.
Biochem Pharmacol. 2018 Dec;158:174-184. doi: 10.1016/j.bcp.2018.10.012. Epub 2018 Oct 17.
本文引用的文献
1
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
J Pharm Sci. 2011 Jun;100(6):2508-15. doi: 10.1002/jps.22457. Epub 2010 Dec 29.
2
Profiling the reactive metabolites of xenobiotics using metabolomic technologies.
Chem Res Toxicol. 2011 May 16;24(5):744-51. doi: 10.1021/tx200033v. Epub 2011 Apr 21.
3
Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
Drugs. 2010 Oct 1;70(14):1885-915. doi: 10.2165/11204950-000000000-00000.
4
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
AIDS. 2009 Apr 27;23(7):863-5. doi: 10.1097/QAD.0b013e328329148e.
5
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81. doi: 10.1097/QAI.0b013e31819c2937.
6
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
AIDS. 2008 May 11;22(8):931-5. doi: 10.1097/QAD.0b013e3282faa71e.
7
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
HIV Clin Trials. 2008 Jan-Feb;9(1):1-10. doi: 10.1310/hct0901-1.
8
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):566-9. doi: 10.1097/QAI.0b013e3181642257.
9
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Curr Drug Metab. 2007 Jun;8(5):407-47. doi: 10.2174/138920007780866807.
10
Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
HIV Clin Trials. 2006 Nov-Dec;7(6):319-23. doi: 10.1310/hct0706-319.
Zotero 插件